{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:48:24Z","timestamp":1793296104543,"version":"4.5.0"},"reference-count":78,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>We evaluated the effectiveness and safety of pan\u2010genotypic regimens, glecaprevir\/pibrentasvir (GLE\/PIB), sofosbuvir\/velpatasvir (SOF\/VEL), and sofosbuvir\/daclatasvir (SOF\/DCV) and other direct\u2010acting antivirals (DAA) regimens for the treatment of hepatitis C virus (HCV)\u2010infected adolescents (12\u201318\u2009years), older children (6\u201311\u2009years), and young children (3\u20135\u2009years). The purpose of this systematic review and meta\u2010analysis was to inform the World Health Organization (WHO) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included clinical trials and observational studies published up to August 11, 2021, that evaluated DAA regimens in HCV\u2010infected adolescents, older children, and young children. We searched MEDLINE, EMBASE, and CENTRAL databases and key conference abstracts. Sustained virological response 12\u2009weeks after the end of treatment (SVR12), adverse events (AEs), and treatment discontinuation were the outcomes evaluated. Risk of bias was assessed using a modified version of the ROBINS\u2010I tool. Data were pooled using random\u2010effects models, and certainty of the evidence was assessed using the GRADE approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 49 studies including 1882 adolescents, 436 older children, and 166 young children were considered. The SVR12 was 100% (95% Confidence Interval: 96\u2013100), 96% (90\u2013100), and 96% (83\u2013100) for GLE\/PIB in adolescents, older, and young children, respectively; 95% (90\u201399), 93% (86\u201398), and 83% (70\u201393), for SOF\/VEL, respectively; and 100% (97\u2013100) and 100% (94\u2013100) for SOF\/DCV in adolescent and older children, respectively. There was a clear trend towards a higher rate of any reported AE from adolescents (50%), older children (53%), to young children (72%). Serious AEs and treatment discontinuations were uncommon in adolescents and older children (&lt;1%) but slightly higher in young children (3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>All three pan\u2010genotypic DAA regimens were highly effective and well\u2010tolerated and are now recommended by the WHO for use in adults, adolescents, and children down to 3\u2009years, which will simplify procurement and supply chain management. The evidence was based largely on single\u2010arm non\u2010randomized controlled studies. Moreover, there were also missing data regarding key variables such as route of HCV acquisition, presence or absence of cirrhosis, or HIV co\u2010infection that precluded evaluation of the impact of these factors on outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:styled-content style=\"fixed-case\">PROSPERO<\/jats:styled-content>\n                      Record\n                    <\/jats:title>\n                    <jats:p>CRD42020146752.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/liv.15827","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T04:18:56Z","timestamp":1706674736000},"page":"663-681","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and safety of\n                    <scp>DAA<\/scp>\n                    in children and adolescents with chronic\n                    <scp>HCV<\/scp>\n                    infection: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3830-9823","authenticated-orcid":false,"given":"Giuseppe","family":"Indolfi","sequence":"first","affiliation":[{"name":"Department Neurofarba University of Florence  Florence Italy"},{"name":"Paediatric and Liver Unit Meyer Children's Hospital IRCCS  Firenze Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2603-5418","authenticated-orcid":false,"given":"Philippa","family":"Easterbrook","sequence":"additional","affiliation":[{"name":"Global HIV, Hepatitis and STI Programmes World Health Organization Headquarters  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-1778","authenticated-orcid":false,"given":"Sabrina","family":"Giometto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2752-5926","authenticated-orcid":false,"given":"Farihah","family":"Malik","sequence":"additional","affiliation":[{"name":"Great Ormond Street Institute of Child Health University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9269-4051","authenticated-orcid":false,"given":"Roger","family":"Chou","sequence":"additional","affiliation":[{"name":"Departments of Medicine, and Medical Informatics &amp; Clinical Epidemiology Oregon Health Sciences University  Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5608-5902","authenticated-orcid":false,"given":"Ersilia","family":"Lucenteforte","sequence":"additional","affiliation":[{"name":"Department of Statistics, Computer Science and Applications \u00abG. Parenti\u00bb University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"e_1_2_14_2_1","unstructured":"WHO.Global progress report on HIV viral hepatitis and sexually transmitted infections 2021.2021. Accessed August 23 2022.https:\/\/www.who.int\/publications\/i\/item\/9789240027077"},{"key":"e_1_2_14_3_1","unstructured":"AASLD\/IDSA.HCV guidance: recommendations for testing managing and treating hepatitis C. AASLD\/IDSA. Aasld\u2010Idsa.2021. Accessed August 23 2022.https:\/\/www.hcvguidelines.org\/"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30046-9"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30385-1"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29278"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30821"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28995"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30123"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30830"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30840"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31841"},{"key":"e_1_2_14_14_1","unstructured":"SokalE SchwarzKB RosenthalP et\u00a0al.Safety and efficacy of sofosbuvir\/velpatasvir for the treatment of chronic hepatitis C infection in adolescents and children aged 3 to 17\u2009years old through 24\u2009weeks post\u2010treatment.2020. Accessed August 23 2022.https:\/\/www.natap.org\/2020\/AASLD\/AASLD_26.htm"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/HEP.32393"},{"key":"e_1_2_14_16_1","unstructured":"Gonzalez\u2010Peralta RP; Wirth Squires SRH;Baumann U;Lang T;PawlowskaM Sluzewski W;Majda\u2010Stanislawska E;Fischler B;Balistreri W;JonasM Xu N;Rosenthal P;Alkhouri N;Romero R;Benner J;Grandhi A;CastronuovoP Haber C;Caro L;HaberB.Development of a Novel Model to Support Elbasvir\/Grazoprevir Use in Children With Chronic Hepatitis C Virus Genotypes 1 or 4 Infection [abstract LP10]. American Association for the Study of Liver Diseases (AASLD) Liver Meeting.2019."},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1250"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01389-9"},{"key":"e_1_2_14_19_1","unstructured":"IndolfiG SerrantiD BettiolA et\u00a0al.Efficacy and safety of direct\u2010acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in children and adolescents: a systematic review and meta\u2010analysis. PROSPERO 2020 CRD42020146752.2020.https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020146752"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16037"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_14_22_1","unstructured":"Package \u2018meta\u2019 Title General Package for Meta\u2010Analysis.2019. doi:10.1007\/978-3-319-21416"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.12.007"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.346.15722"},{"key":"e_1_2_14_27_1","first-page":"423","article-title":"Effectiveness and safety of sofosbuvir in treatment\u2010N\u00e4ive children with hepatitis C infection","volume":"27","author":"Hashmi MA","year":"2017","journal-title":"J Coll Physicians Surg Pak"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2019.12.034"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002139"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09985-w"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101747"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002101"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14502"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001360"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002894"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001838"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14677"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i16.2247"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/apa.15333"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002189"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piz041"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13032"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14308"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaa006"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2017.06.002"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2021.02.012"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-018-2752-7"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001217"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002900"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001968"},{"key":"e_1_2_14_51_1","unstructured":"El\u2010SayedMH KabilK EbeidF et\u00a0al.#OS\u20102306. DAA therapy in HCV\u2010infected Egyptian children: real\u2010life model from a multicentre program supported by an NGO.Presented at EALS2021."},{"key":"e_1_2_14_52_1","unstructured":"HirschC Badue PereiraMF BernardesT et\u00a0al.#P0824\/#2279. Direct\u2010acting antivirals for children with chronic hepatitis C: a BRAZILIAN single center experience.Presented at ESPID2020."},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30748-7"},{"key":"e_1_2_14_54_1","unstructured":"BansalS Paw\u0142owskaM NebbiaG et\u00a0al.Safety and efficacy of Sofosbuvir\/Velpatasvir\/Voxilaprevir in adoloscents with chronic hepatitis C virus infection. The Liver Meeting. Digital Experience. AASLD. November 13\u201316\u20132020.2020. Accessed August 23 2022.https:\/\/www.natap.org\/2020\/AASLD\/AASLD_25.htm"},{"key":"e_1_2_14_55_1","unstructured":"WirthS Gonzalez\u2010PeraltaRP SquiresRH et\u00a0al.Elbasvir\/Grazoprevir in children aged 3 to <18\u2009years with chronic hepatits C virus (HCV) genotype (GT) 1 or 4 infection: final results from an iterative pharmacokinetic (PK) modeling study.2020;909."},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30388-3"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30642-6"},{"key":"e_1_2_14_58_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)30411-6","article-title":"Ledipasvir\/sofosbuvir for 8\u2009weeks cures genotype 4 chronic hepatitis C in non\u2010cirrhotic children and adolescents (abstr)","volume":"70","author":"El\u2010Sayed MH","year":"2019","journal-title":"J Hepatol"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)31278-9"},{"key":"e_1_2_14_60_1","article-title":"Outcomes of sofosbuvir and ribavirin treatment combination in HEP C G3 pediatric patients (abstr)","volume":"12","author":"Gill ML","year":"2018","journal-title":"Hepatol Int"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000593684.36839.aa"},{"key":"e_1_2_14_62_1","first-page":"950","article-title":"Effectiveness and safety of sofosbuvir in chronic hepatitis C virus infection of Bangladeshi children (abstr)","volume":"72","author":"Mahmud S","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_14_63_1","article-title":"Hepatic involvement and HCV status among Egyptian children with Gaucher disease (abstr)","volume":"72","author":"Megahed A","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_14_64_1","article-title":"Ledipasvir (LDV) and daclatasvir (DCT) in thalassemic patients with chronic hepatitis C: a single center experience (abstr)","volume":"35","author":"Patel R","year":"2016","journal-title":"Indian J Gastroenterol"},{"key":"e_1_2_14_65_1","unstructured":"WHO.Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection.2018. Accessed August 23 2022.https:\/\/www.who.int\/publications\/i\/item\/9789241550345"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy585"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16037"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.04859.x"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318185998f"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.14661\/2015.1214-1219"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001754"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12830"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.12.012"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/inf.0000000000003282"},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002725"},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32393"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000031"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003406"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEPR.2021.100227"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.15827","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.15827","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.15827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:01:04Z","timestamp":1773014464000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.15827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/liv.15827"],"URL":"https:\/\/doi.org\/10.1111\/liv.15827","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"2023-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}